X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (401) 401
Publication (88) 88
Paper (54) 54
Book / eBook (10) 10
Book Chapter (6) 6
Dissertation (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (128) 128
index medicus (101) 101
female (93) 93
male (91) 91
middle aged (78) 78
adult (67) 67
aged (67) 67
nuclear experiment (59) 59
oncology (57) 57
experiment (55) 55
physics (51) 51
nuclear physics (45) 45
high energy physics - experiment (41) 41
cancer (40) 40
endocrinology & metabolism (36) 36
treatment outcome (33) 33
mutation (32) 32
carcinoma (31) 31
chemotherapy (28) 28
particle physics (28) 28
prognosis (28) 28
abridged index medicus (27) 27
aged, 80 and over (27) 27
adolescent (25) 25
high energy physics (25) 25
survival (25) 25
thyroid cancer (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
nucl (23) 23
retrospective studies (23) 23
114 physical sciences (22) 22
[phys.nexp]physics [physics]/nuclear experiment [nucl-ex] (22) 22
hep (22) 22
physics of elementary particles and fields (22) 22
therapy (22) 22
thyroid neoplasms - pathology (22) 22
management (21) 21
thyroid neoplasms - drug therapy (21) 21
antineoplastic agents - therapeutic use (20) 20
otorhinolaryngology (20) 20
research (20) 20
young adult (20) 20
analysis (19) 19
care and treatment (19) 19
disease-free survival (19) 19
nuclear and high energy physics (19) 19
patients (19) 19
article (17) 17
hematology (17) 17
tumors (17) 17
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (16) 16
animals (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
ex (16) 16
metastasis (15) 15
surgery (15) 15
survival rate (15) 15
thyroid (15) 15
thyroid neoplasms - mortality (15) 15
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
diagnosis (14) 14
matematikk og naturvitenskap: 400::fysikk: 430::kjerne- og elementærpartikkelfysikk: 431 [vdp] (14) 14
mathematics and natural scienses: 400::physics: 430::nuclear and elementary particle physics: 431 [vdp] (14) 14
metastases (14) 14
mutations (14) 14
neoplasm staging (14) 14
papillary (14) 14
vincristine - administration & dosage (14) 14
protein kinase inhibitors - therapeutic use (13) 13
[ phys.nexp ] physics [physics]/nuclear experiment [nucl-ex] (12) 12
cern lhc coll (12) 12
double-blind (12) 12
expression (12) 12
follow-up studies (12) 12
heavy ion experiments (12) 12
melanoma (12) 12
transverse momentum (12) 12
cohort studies (11) 11
lymphomas (11) 11
radiotherapy (11) 11
sorafenib (11) 11
thyroid neoplasms - genetics (11) 11
combined modality therapy (10) 10
cyclophosphamide - administration & dosage (10) 10
dexamethasone - administration & dosage (10) 10
doxorubicin - administration & dosage (10) 10
lymphoma, non-hodgkin - drug therapy (10) 10
phase-ii trial (10) 10
protein kinase inhibitors - adverse effects (10) 10
proteins (10) 10
proto-oncogene proteins b-raf - genetics (10) 10
risk (10) 10
thyroid cancer and nodules (10) 10
thyroid neoplasms - surgery (10) 10
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (9) 9
automatic keywords (9) 9
biomarkers (9) 9
braf (9) 9
child (9) 9
clinical trials (9) 9
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (345) 345
Spanish (62) 62
Portuguese (14) 14
Romance (2) 2
Catalan (1) 1
Galician (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Endocrine Reviews, ISSN 0163-769X, 07/2019, Volume 40, Issue 6, pp. 1573 - 1604
The treatment of advanced thyroid cancer has undergone rapid evolution in the past decade, with multiple kinase inhibitor drug approvals for each subtype of... 
Journal Article
Seminars in Oncology, ISSN 0093-7754, 02/2019, Volume 46, Issue 1, pp. 57 - 64
Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors 1-4, RET, KIT, and... 
Adverse event | Lenvatinib | Tyrosine kinase inhibitor | Differentiated thyroid cancer | Side effect | MANAGEMENT | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | REVERSIBLE ENCEPHALOPATHY SYNDROME | ANTITUMOR ACTIVITIES | RENAL-CELL CARCINOMA | BLOOD-PRESSURE | E7080 | TARGETED THERAPIES | ONCOLOGY | HYPERTENSION
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2933 - 2933
Objective: 
Journal Article
Head & Neck, ISSN 1043-3074, 08/2016, Volume 38, Issue 8, pp. 1290 - 1290
Journal Article
The Oncologist, ISSN 1083-7159, 8/2014, Volume 19, Issue 8, pp. e4 - e4
Sarcopenia caused by hyperthyroidism from thyroid-stimulating hormone-suppressive therapy is one possible explanation for sorafenib dose-limiting toxicity in... 
Letters to the Editor
Journal Article
The Oncologist, ISSN 1083-7159, 08/2014, Volume 19, Issue 8, pp. e4 - e4
Sarcopenia caused by hyperthyroidism from thyroid‐stimulating hormone‐suppressive therapy is one possible explanation for sorafenib dose‐limiting toxicity in... 
Journal Article
Head & Neck, ISSN 1043-3074, 08/2016, Volume 38, Issue 8, pp. 1290 - 1290
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e17580 - e17580
Journal Article
Oncologist, ISSN 1083-7159, 2014, Volume 19, Issue 8, p. e4
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 6085 - 6085
Journal Article
Respiratory Medicine Case Reports, ISSN 2213-0071, 2019, Volume 26, pp. 197 - 199
Spontaneous pneumothorax is rarely associated with cancer. We describe a 73 year old man who presented with recurrent tumor in the right neck, mediastinal... 
Pneumothorax | Anaplastic thyroid cancer | Lenvatinib | Targeted therapy | Case Report
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e17547 - e17547
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1272 - 1282
Summary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase... 
Hematology, Oncology and Palliative Medicine
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2015, Volume 42, pp. 47 - 55
Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase... 
Hematology, Oncology and Palliative Medicine | Refractory | Medullary | Advanced | Multikinase | Survival | Differentiated | PHOSPHATIDYLINOSITOL 3-KINASE/AKT | MEDULLARY CARCINOMA | BRAF | ANTITUMOR ACTIVITIES | E7080 | ONCOLOGY | DOUBLE-BLIND | TYROSINE KINASE INHIBITOR | PAPILLARY | PHASE-I | GENETIC ALTERATIONS | Thyroid Neoplasms - enzymology | Humans | Receptors, Growth Factor - antagonists & inhibitors | Infant | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Everolimus - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Quinolines - administration & dosage | Quinolines - pharmacology | Thyroid Neoplasms - therapy | Iodine Radioisotopes - therapeutic use | Multicenter Studies as Topic | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Carcinoma - enzymology | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Carcinoma - drug therapy | Carboplatin - administration & dosage | Neoplasms - enzymology | Phenylurea Compounds - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Thyroidectomy | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Phenylurea Compounds - administration & dosage | Signal Transduction - drug effects | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Carcinoma - therapy | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Quinolines - adverse effects | Development and progression | Thyroid cancer | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article